Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Aug
05
Today In Oncology
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma
Combination Regimen Prolongs PFS in dMMR-MSI-H Metastatic Colorectal Cancer
CKM Syndrome Associated With Increased, Stage-Specific Cancer Risk, Study Finds
Population-Based MGUS Screening Enables Earlier Detection of Multiple Myeloma Without Increasing Psychological Distress
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo